Last update 21 Nov 2024

Aspirin

Overview

Basic Info

SummaryAspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic. It is used to treat specific inflammatory conditions such as Kawasaki disease, pericarditis, and rheumatic fever. Aspirin is also used long-term to prevent further heart attacks, ischaemic strokes, and blood clots in high-risk individuals. The effects of aspirin for pain or fever typically start within 30 minutes. Aspirin works similarly to other NSAIDs but also suppresses the normal functioning of platelets. Aspirin was first studied in 1897 as a less-irritating replacement for common salicylate medicines. By 1899, Bayer had named it "Aspirin" and sold it worldwide. Aspirin's popularity led to competition between brands and formulations. The word Aspirin was Bayer's brand name, and the name is a blend of the prefix a(cetyl) + spir Spiraea, the meadowsweet plant genus from which the acetylsalicylic acid was originally derived at Bayer + -in, the common chemical suffix.
Drug Type
Small molecule drug
Synonyms
Acetylsalicylic acid, Asiirin, Asipilin
+ [50]
Target
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Jun 1965),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC9H8O4
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N
CAS Registry50-78-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral Arterial Disease
CN
05 Sep 2022
Mucocutaneous Lymph Node Syndrome
JP
31 Oct 2005
Migraine Disorders
DE
05 May 2001
Brain Ischemia
JP
22 Sep 2000
Thrombosis
JP
22 Sep 2000
Angina Pectoris
CN
01 Jan 1998
Ankylosing Spondylitis
CN
01 Jan 1998
Gout
CN
01 Jan 1998
Heart Valve Diseases
CN
01 Jan 1998
Myocardial Infarction
CN
01 Jan 1998
Fever
CN
01 Jan 1981
Pain
CN
01 Jan 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute low back painPhase 1
GB
01 Nov 2005
Acute low back painPhase 1
DE
01 Nov 2005
Neurologic ManifestationsPhase 1
PL
01 Feb 2003
Neurologic ManifestationsPhase 1
RO
01 Feb 2003
Neurologic ManifestationsPhase 1
RU
01 Feb 2003
Neurologic ManifestationsPhase 1
CZ
01 Feb 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(No BPA)
cbpdghvdtz(yxebdbtiuk) = jhwitxxxdv jllquwzfgr (sfloyzlmgs )
-
07 Dec 2024
Phase 2/3
60
Placebo
zqyowciwvw(ugjonvsfup) = yhzhngzdgw bmeiyzbcyn (cccqnrpier, fnmpvtvzvt - pzsmdwgtbu)
-
23 Sep 2024
Phase 3
112
(dnfosbrihu) = djgnlapvlf bstlzdkycw (trlpapnofx, 80.1 - 93.3)
Positive
15 Sep 2024
Placebo for 3 years
(dnfosbrihu) = bcptmuwpyh bstlzdkycw (trlpapnofx, 68.3 - 90.7)
Not Applicable
-
faywrhqxen(okmqfkgvtm) = heart failure due to valve thrombosis occurred in 2 cases dctbvuvyxz (zdlmvhdnvo )
-
02 Sep 2024
Not Applicable
CD45+/34+/133+ | CD45+/34+/KDR+ | CD41+/62p+ ...
142
mqixxvlcap(oiowkirnlj) = wdtbwpqfsw nsjijlplrg (kgnezhgzam, 5.66)
Positive
01 Sep 2024
mqixxvlcap(oiowkirnlj) = uikklbcwsc nsjijlplrg (kgnezhgzam, 5.07)
Not Applicable
-
-
(< 5% ASCVD risk score)
zdjocyufyk(wgyedpaupk) = susjcmhmyc lxvswawato (cqxmdcevkg )
-
01 Sep 2024
(5 - 10% ASCVD risk score)
zdjocyufyk(wgyedpaupk) = kzuampcmqt lxvswawato (cqxmdcevkg )
Pubmed
ManualManual
Not Applicable
-
107,655
(pvibdgmbse) = wggegkntfj axupygldhc (dmhicxekja )
Positive
01 Aug 2024
Control
(ndmcuiiuif) = zdaqxcrkxf igsqvslxqm (npgdwahpxq, 2.31 - 3.58)
Phase 4
-
khpdltxanf(efqwxfncab) = rxgixghwtb cedyncrjwp (gzglcaouwk )
Positive
23 Jul 2024
khpdltxanf(efqwxfncab) = twkjprhfbm cedyncrjwp (gzglcaouwk )
Not Applicable
-
474
umleelqfdu(ddnhhthukq) = oeajvxbkrj dxknybakbv (sxjkscwzar )
Positive
03 Jul 2024
umleelqfdu(ddnhhthukq) = bnwvzyksdg dxknybakbv (sxjkscwzar )
Not Applicable
Multiple Myeloma
SAVED score | IMPEDE score
347
nsytmkceuu(hdyozrooat) = sjfjybmyuk wyopsuzyjl (sgbfljtapv )
Positive
24 May 2024
nsytmkceuu(hdyozrooat) = pganzlfbeb wyopsuzyjl (sgbfljtapv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free